Sulfaphenazole: Benchmark CYP2C9 Inhibitor for Drug Metabolism Modulation

Executive Summary: Sulfaphenazole is a potent, selective, and competitive inhibitor of cytochrome P450 2C9 (CYP2C9) with a Ki of 0.3 ± 0.1 μM under standardized in vitro conditions, enabling precise modulation of drug metabolism (Chen et al., 2021). It displays negligible activity against related P450 isoforms, minimizing off-target effects. In vivo, sulfaphenazole restores endothelial function in diabetic mouse models by reducing oxidative stress and increasing nitric oxide bioavailability. APExBIO's Sulfaphenazole (SKU: C4131) is validated for scientific research use and is not intended for diagnostic or clinical application (APExBIO). Structured protocols and robust benchmarking studies establish sulfaphenazole as the preferred tool for pharmacogenetic, drug-drug interaction, and vascular research workflows.

Biological Rationale

CYP2C9 is a major human liver enzyme responsible for metabolizing numerous clinically important drugs, including warfarin, phenytoin, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral hypoglycemics (Chen et al., 2021). Genetic polymorphisms in CYP2C9 can lead to variable drug responses and increased risk of adverse drug reactions. Pharmacological inhibition of CYP2C9 with a selective agent allows researchers to dissect metabolic pathways, evaluate drug-drug interactions, and model pharmacogenetic outcomes in preclinical systems. Sulfaphenazole’s competitive inhibition profile, selectivity, and reproducibility make it an essential reference inhibitor for such studies. Its ability to modulate endothelial function in disease models (e.g., diabetes) also broadens its utility to vascular pharmacology research (See also: Harnessing CYP2C9 Inhibition—this article updates prior coverage by detailing quantitative benchmarks and workflow integration best practices).

Mechanism of Action of Sulfaphenazole

Sulfaphenazole acts as a selective, competitive inhibitor by binding to the active site of CYP2C9, preventing substrate access and subsequent metabolism (Chen et al., 2021). This binding is characterized by a Ki value of 0.3 ± 0.1 μM, determined under controlled in vitro conditions using human recombinant enzymes. The molecule’s 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide scaffold is critical for its affinity and specificity. Sulfaphenazole exhibits significantly weaker inhibition of CYP2C8 and CYP2C18 and no detectable inhibition of CYP1A1, CYP1A2, CYP3A4, or CYP2C19 at concentrations up to 10 μM. This high selectivity is essential for probing CYP2C9-specific metabolic events without confounding off-target effects (See also: Potent Competitive CYP2C9 Inhibitor—this article clarifies chemical specificity and selectivity profiles in comparison to broader reviews).

Evidence & Benchmarks

• Sulfaphenazole inhibits CYP2C9 with a Ki of 0.3 ± 0.1 μM in human recombinant enzyme assays, providing robust selectivity over other P450 isoforms (DOI).
• It does not inhibit CYP1A1, CYP1A2, CYP3A4, or CYP2C19 at concentrations up to 10 μM, confirming low risk of off-target interactions (DOI, Table 1).
• In diabetic db/db mice, daily intraperitoneal administration (5.13 mg/kg, 8 weeks) restored endothelium-dependent vasodilation by reducing oxidative stress and increasing nitric oxide bioavailability (APExBIO).
• Derivative optimization of the sulfaphenazole scaffold demonstrates that the 4-aminobenzenesulfonamide moiety is essential for both antimycobacterial activity and CYP2C9 inhibition (DOI, SAR section).
• APExBIO’s Sulfaphenazole (C4131) is chemically defined as 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide (MW 314.4, CAS 526-08-9), supplied for research use only (Product page).

Applications, Limits & Misconceptions

Applications:

• Reference inhibitor for CYP2C9 in drug-drug interaction, metabolic pathway, and pharmacogenetics studies (Applied Use of Sulfaphenazole—this article extends coverage by providing updated storage, solubility, and in vivo use parameters).
• Experimental modulator in vascular endothelial function assays, especially in diabetic and oxidative stress models (Benchmark CYP2C9 Inhibitor—this article complements the present review by focusing on translational vascular endpoints).
• Control compound in adverse drug reaction risk assessment workflows and pharmacokinetic modeling.
• Tool for structure-activity relationship (SAR) studies in the optimization of sulfonamide derivatives with reduced CYP2C9 inhibition.

Common Pitfalls or Misconceptions

• Sulfaphenazole is not a pan-CYP inhibitor; its negligible activity against CYP3A4, CYP1A1, CYP1A2, and CYP2C19 must be considered in multi-enzyme studies.
• It is not suitable for clinical or diagnostic use; APExBIO’s Sulfaphenazole is for research applications only (Product page).
• Long-term storage of prepared solutions is discouraged due to stability limitations—fresh aliquots are recommended for each experiment.
• Its poor water solubility (soluble in DMSO ≥13.15 mg/mL; ethanol ≥9.92 mg/mL with ultrasonic assistance) requires careful solvent selection and validation of vehicle controls.
• CYP2C9 inhibition by sulfaphenazole in vitro may not fully recapitulate complex in vivo pharmacogenetic scenarios—model selection should match research intent.

Workflow Integration & Parameters

Sulfaphenazole (C4131) from APExBIO is supplied as a chemically defined powder. It should be reconstituted in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL with ultrasonic assistance) for stock solutions. For optimal stability, store at -20°C and avoid repeated freeze-thaw cycles; use freshly prepared solutions whenever possible. In cell-based or enzyme assays, recommended working concentrations range from 0.1 to 10 μM, with specific optimization based on the target system. In vivo, the dose of 5.13 mg/kg/day (intraperitoneal, 8 weeks) has been validated for vascular studies in diabetic db/db mice. Always include vehicle controls and verify target engagement via standard CYP2C9 activity assays. For workflow troubleshooting and advanced integration, see Applied Use of Sulfaphenazole (this article extends by including recent stability and solubility data).

Conclusion & Outlook

Sulfaphenazole remains the benchmark competitive CYP2C9 inhibitor for preclinical drug metabolism modulation and vascular research. Its high selectivity, defined mechanism, and reproducibility make it indispensable for mechanistic and translational studies in pharmacogenetics, drug-drug interaction risk, and endothelial function. Ongoing optimization of sulfonamide scaffolds aims to separate antimicrobial from CYP2C9 inhibitory activity, broadening research and potential therapeutic applications (Chen et al., 2021). For validated protocols and high-purity material, APExBIO’s Sulfaphenazole (C4131) is recommended as a gold-standard research tool (Product page).